Renoprotective Potency of Sitagliptin versus Pioglitazone in Type 2 Diabetic Patients: Impact on LncMIAT

Renoprotective Potency of Sitagliptin versus Pioglitazone in Type 2 Diabetic Patients: Impact on LncMIAT

Bibliographic Details
Main Authors:	Mohamed A. Kandeil, Mohamed A. Shaarawy, Hamdy A. Mourad, Mohamed O. Mahmoud
Format:	Article
Language:	English
Published:	American Chemical Society 2023-11-01
Series:	ACS Omega
Online Access:	https://doi.org/10.1021/acsomega.3c07008

Similar Items

NPM promotes hepatotoxin-induced fibrosis by inhibiting ROS-induced apoptosis of hepatic stellate cells and upregulating lncMIAT-induced TGF-β2
by: Xue Ding, et al.
Published: (2023-08-01)

Effect of sitagliptin on proteinuria in patients with type 2 diabetes - A renoprotective effect of sitagliptin
Published: (2021-01-01)

Puzzling out the role of MIAT LncRNA in hepatocellular carcinoma
by: Rawan Amr Elmasri, et al.
Published: (2024-06-01)

Inhibition of the lncRNA MIAT prevents podocyte injury and mitotic catastrophe in diabetic nephropathy
by: Ziyang Wang, et al.
Published: (2022-06-01)

Additive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARs.
by: Mai M Helmy, et al.
Published: (2015-01-01)

Renoprotective and haemodynamic effects of adiponectin and peroxisome proliferator-activated receptor agonist, pioglitazone, in renal vasculature of diabetic Spontaneously hypertensive rats.
by: Sheryar Afzal, et al.
Published: (2020-01-01)

MIAT LncRNA: A multifunctional key player in non-oncological pathological conditions
by: Yousra Zeinelabdeen, et al.
Published: (2024-06-01)

Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma
by: Katia Todoerti, et al.
Published: (2021-11-01)

Association between Genetic Polymorphism of The lncRNA MIAT rs1894720 with Ischemic Stroke Risk and lncRNA MIAT Expression Levels in The Blood after An Ischemic Stroke: A Case-Control Study
by: Tahereh Asadabadi, et al.
Published: (2023-12-01)

Downregulation of lncRNA Miat contributes to the protective effect of electroacupuncture against myocardial fibrosis
by: Wenchuan Qi, et al.
Published: (2022-05-01)

Efficacy and safety of fixed dose combination of Sitagliptin, metformin, and pioglitazone in type 2 Diabetes (IMPACT study): a randomized controlled trial
by: Mondal Aashish, et al.
Published: (2024-02-01)

lncRNA-MIAT rs9625066 polymorphism could be a potential biomarker for ischemic stroke
by: Yin-Hua Weng, et al.
Published: (2024-02-01)

LncRNA MIAT Promotes the Proliferation and Invasion of Colorectal Cancer via Suppressing Apoptosis and Senescence
by: Farzane Amirmahani, et al.
Published: (2023-04-01)

Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients
by: Antonio Asti, et al.
Published: (2016-03-01)

LncRNA-MIAT activates hepatic stellate cells via regulating Hippo pathway and epithelial-to-mesenchymal transition
by: Yating Zhan, et al.
Published: (2023-03-01)

Role of lncRNA MIAT/miR-361-3p/CCAR2 in prostate cancer cells
by: Feng Tao, et al.
Published: (2022-09-01)

LncRNA-MIAT-Mediated miR-214-3p Silencing Is Responsible for IL-17 Production and Cardiac Fibrosis in Diabetic Cardiomyopathy
by: Yanqing Qi, et al.
Published: (2020-04-01)

Early Renoprotective Effect of Ruxolitinib in a Rat Model of Diabetic Nephropathy
by: Mohamed M. El-Kady, et al.
Published: (2021-06-01)

Association of Angio-LncRNAs MIAT rs1061540/MALAT1 rs3200401 Molecular Variants with Gensini Score in Coronary Artery Disease Patients Undergoing Angiography
by: Mohamed Y. Elwazir, et al.
Published: (2022-01-01)

Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease
by: Saba Sayari, et al.
Published: (2018-09-01)

ADSC Exosomes Mediate lncRNA-MIAT Alleviation of Endometrial Fibrosis by Regulating miR-150-5p
by: Xiaowen Shao, et al.
Published: (2021-06-01)

A comparative study of the cardioprotective effect of Metformin, Sitagliptin and Dapagliflozin on Isoprenaline induced myocardial infarction in non-diabetic rats
by: Mostafa Mahmoud Ibrahim, et al.
Published: (2022-04-01)

Diabetic nephropathy. Is renoprotection determined by the choice of hypoglycemic therapy?
by: A. Y. Babenko, et al.
Published: (2015-12-01)

Pioglitazone abrogates testicular damage induced by testicular torsion/detorsion in rats
by: Nevertyty Mohamed Mahmoud, et al.
Published: (2019-08-01)

Author Correction: LncRNA-MIAT activates hepatic stellate cells via regulating Hippo pathway and epithelial-to-mesenchymal transition
by: Yating Zhan, et al.
Published: (2024-01-01)

MIAT Is an Upstream Regulator of NMYC and the Disruption of the MIAT/NMYC Axis Induces Cell Death in <i>NMYC</i> Amplified Neuroblastoma Cell Lines
by: Barbara Feriancikova, et al.
Published: (2021-03-01)

HYPOGLYCEMIC EFFECT OF SITAGLIPTIN AND AMINOGUANIDINE COMBINATION IN EXPERIMENTAL DIABETES MELLITUS
by: D. V. Kurkin, et al.
Published: (2023-02-01)

Silence of lncRNA MIAT protects ATDC5 cells against lipopolysaccharides challenge via up-regulating miR-132
by: Chen Li, et al.
Published: (2019-12-01)

CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece
by: Ghetti G, et al.
Published: (2023-02-01)

Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy
by: Lorenzoni V, et al.
Published: (2017-11-01)

The potential renoprotection of xanthine oxidase inhibitors: Febuxostat versus allopurinol
by: Dong-Ryeol Ryu
Published: (2017-09-01)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
by: Shannon A Miller, et al.
Published: (2009-05-01)

Kidney protective effect of sitagliptin in 5-fluorouracil-challenged rats
by: Ahmed Hassan Al-Ghamdi, et al.
Published: (2024-02-01)

LncRNA MIAT Upregulates NEGR1 by Competing for miR-150-5p as a Competitive Endogenous RNA in SCIRI Rats
by: Zheng Wang, et al.
Published: (2022-01-01)

Correspondence on sitagliptin and cardiovascular outcomes in type 2 diabetes
by: Holman, R, et al.
Published: (2015)

Comparative study on efficacy of empagliflozin versus sitagliptin, as an add-on therapy to metformin in type 2 diabetic patients
by: Harsh Salankar, et al.
Published: (2024-01-01)

Evaluation of Metformin + Sitagliptin versus Metformin + Glibenclamide on Glycemic Control in Iraqis Type 2 Diabetic Patients
by: Hassan M. Al-Temimi, et al.
Published: (2017-03-01)

The Safety and Efficacy of Combining Saxagliptin and Pioglitazone Therapy in Streptozocin-Induced Diabetic Rats
by: Ahmed Mohamed Othman, et al.
Published: (2023-12-01)

Hepatoprotective effect of sitagliptin against methotrexate induced liver toxicity.
by: Hany M Abo-Haded, et al.
Published: (2017-01-01)

Renoprotective Effects of Trigonella foenum and Cinnamon on Type 2 Diabetic Rats
by: M.Kassaee, et al.
Published: (2017-06-01)